Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
David Hoang is an analyst at Citigroup. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $31.58 | 42.5% | $40 → $45 | Maintains | Buy | Get Alert |
| 06/26/2024 | SRPT | Buy Now | Sarepta Therapeutics | $151.47 | 16.19% | $172 → $176 | Downgrade | Buy → Neutral | Get Alert |
| 06/21/2024 | HRMY | Buy Now | Harmony Biosciences | $32.54 | 47.51% | → $48 | Initiates | → Buy | Get Alert |
| 05/29/2024 | SAGE | Buy Now | Sage Therapeutics | $10.94 | -26.87% | → $8 | Initiates | → Sell | Get Alert |
| 05/10/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $37.19 | 61.33% | $62 → $60 | Maintains | Buy | Get Alert |
| 05/09/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.32 | 83.82% | $30.19 → $30 | Maintains | Buy | Get Alert |
| 05/07/2024 | AXSM | Buy Now | Axsome Therapeutics | $83.62 | 49.49% | $127 → $125 | Maintains | Buy | Get Alert |
| 05/03/2024 | NBIX | Buy Now | Neurocrine Biosciences | $142.24 | 5.46% | $140 → $150 | Maintains | Neutral | Get Alert |
| 03/26/2024 | AXSM | Buy Now | Axsome Therapeutics | $83.62 | 51.88% | $125 → $127 | Maintains | Buy | Get Alert |
| 03/15/2024 | SLDB | Buy Now | Solid Biosciences | $6.70 | 138.81% | → $16 | Initiates | → Buy | Get Alert |
| 03/12/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.32 | 84.99% | $38 → $30.19 | Maintains | Buy | Get Alert |
| 03/07/2024 | VYGR | Buy Now | Voyager Therapeutics | $7.41 | 115.92% | → $16 | Initiates | → Buy | Get Alert |
| 02/29/2024 | SRPT | Buy Now | Sarepta Therapeutics | $151.47 | 13.55% | $160 → $172 | Maintains | Buy | Get Alert |
| 02/16/2024 | LBPH | Buy Now | Longboard Pharmaceuticals | $31.58 | 26.66% | → $40 | Initiates | → Buy | Get Alert |
| 02/08/2024 | NBIX | Buy Now | Neurocrine Biosciences | $142.24 | -1.57% | $141 → $140 | Maintains | Neutral | Get Alert |
| 01/04/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $37.19 | 66.71% | → $62 | Initiates | → Buy | Get Alert |
| 12/13/2023 | DNLI | Buy Now | Denali Therapeutics | $21.17 | 51.16% | → $32 | Initiates | → Buy | Get Alert |
| 12/13/2023 | NBIX | Buy Now | Neurocrine Biosciences | $142.24 | -10.71% | → $127 | Initiates | → Neutral | Get Alert |
| 12/13/2023 | ACAD | Buy Now | ACADIA Pharmaceuticals | $16.32 | 132.84% | → $38 | Initiates | → Buy | Get Alert |
| 12/13/2023 | SRPT | Buy Now | Sarepta Therapeutics | $151.47 | -25.4% | → $113 | Initiates | → Buy | Get Alert |
| 12/13/2023 | AXSM | Buy Now | Axsome Therapeutics | $83.62 | 49.49% | → $125 | Initiates | → Buy | Get Alert |
| 04/26/2023 | ALNY | Buy Now | Alnylam Pharmaceuticals | $255.11 | -13.76% | → $220 | Initiates | → Neutral | Get Alert |
| 04/26/2023 | ARWR | Buy Now | Arrowhead Pharma | $25.57 | 212.87% | → $80 | Initiates | → Outperform | Get Alert |
| 04/26/2023 | SRPT | Buy Now | Sarepta Therapeutics | $151.47 | 22.13% | → $185 | Initiates | → Outperform | Get Alert |
| 03/14/2023 | PRVB | Buy Now | Provention Bio | — | — | $15 → $25 | Downgrade | Outperform → Neutral | Get Alert |
| 12/07/2022 | GOSS | Buy Now | Gossamer Bio | $1.15 | 160.87% | → $3 | Downgrade | Outperform → Neutral | Get Alert |
| 04/01/2022 | ORTX | Buy Now | Orchard Therapeutics | — | — | — | Downgrade | Outperform → Neutral | Get Alert |
